Dr. Usmani on the Gimema-MMY-3006 Study for Multiple Myeloma

Video

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the phase III Gimema-MMY-3006 study for patients with multiple myeloma.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the phase III Gimema-MMY-3006 study for patients with multiple myeloma.

MMprofiler is a gene expression profiling tool that is going to be commercialized in the United States, explains Usmani. The Gimema-MMY-3006 study investigated MMprofiler with SKY92 for patients with high- and low-risk of relapse.

SKY92 can independently prognosticate patients who are at the highest risk for disease relapse. According to Usmani, the field is at the point where there is a better prognostication as well as molecular subclass identification of myeloma with gene expression profiling.

Related Videos
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD
Don S. Dizon, MD